Featured Stories
First DePuy ASR Hip Implant Lawsuits Head to Trial in December, January

First DePuy ASR Hip Implant Lawsuits Head to Trial in December, January

The first trials involving lawsuits filed against DePuy Orthopaedics by recipients of its recalled ASR Hip Implants will begin later this year, and early next year. The first is slated to start on December 3, 2012 in state court in Las Vegas, Nevada. A second DePuy ASR hip implant lawsuit ...

Read More

Another Metal-on-Metal Hip Replacement Lawsuit Filed in DePuy ASR Hip Implant Litigation

Another Metal-on-Metal Hip Replacement Lawsuit Filed in DePuy ASR Hip Implant Litigation

A vital food safety program was saved from budget cuts this week, enabling the country’s largest—although considered by experts to be far too small—produce-safety testing program to continue.

Read More

New Study Links Metal-on-Metal Hip Replacement Corrosion with Adverse Local Tissue Reactions

New Study Links Metal-on-Metal Hip Replacement Corrosion with Adverse Local Tissue Reactions

Yet another study is pointing to potential dangers posed by metal-on-metal hip implants. This time, an article published in the Journal of Arthroplasty is reporting corrosion in the head taper junction was more likely to occur in patients with 36-mm diameter metal-on-metal hip replacement, compared to those with the same ...

Read More

Actos Side Effects Lawyers Says Whistleblower Revelations Could Boost Bladder Cancer, Heart Failure Lawsuits

Actos Side Effects Lawyers Says Whistleblower Revelations Could Boost Bladder Cancer, Heart Failure Lawsuits

An attorney with a prominent personal injury law firm says an Actos whistleblower lawsuit filed earlier this year could strengthen legal claims alleging the type 2 diabetes medication caused some users to develop bladder cancer and heart failure.

Read More

Study Linking Z-Pak to Increased Death Risk Being Reviewed by FDA

Study Linking Z-Pak to Increased Death Risk Being Reviewed by FDA

The U.S. Food & Drug Administration (FDA) is reviewing a new study that reported an increased risk of sudden, heart-related deaths among people using the antibiotic Zithromax (azithromycin), known popularly as Z-Pak. In a statement issued late yesterday, the FDA said patients being treated with Zithromax should not stop taking ...

Read More

Parker Waichman Representing Another Louisiana Plaintiff in Actos Bladder Cancer Lawsuit

Parker Waichman Representing Another Louisiana Plaintiff in Actos Bladder Cancer Lawsuit

A Louisiana man has become the latest to claim that his taking the type 2 diabetes drug Actos resulted in developing bladder cancer. He has filed a lawsuit against the Japanese manufacturer of the drug and the marketer of it in the U.S., claiming they failed to warn about this ...

Read More

Canadian Study Confirms Actos Bladder Cancer Risk

Canadian Study Confirms Actos Bladder Cancer Risk

A new study conducted by Canadian researchers has found that users of the type 2 diabetes drug, Actos (pioglitazone), may face a higher risk of developing bladder cancer than first thought. The study, published in the British Medical Journal, found that taking Actos for two years doubles the likelihood ...

Read More

Medtronic Sprint Fidelis Leads Vulnerable to Fracture after ICD Switch

Medtronic Sprint Fidelis Leads Vulnerable to Fracture after ICD Switch

Medtronic Sprint Fidelis leads are vulnerable to fracture following ICD switch, says a new study published in the June issue of the journal Heart Rhythm.

Read More

Newly-Filed Plavix Lawsuits Claim Drug Caused Gastrointestinal Bleeds, Cerebral Hemorrhage, and TTP

Newly-Filed Plavix Lawsuits Claim Drug Caused Gastrointestinal Bleeds, Cerebral Hemorrhage, and TTP

The manufacturer of Plavix continues to be named in lawsuits alleging the blood thinner caused some patients to suffer from serious bleeding side effects. Most recently, the national law firm of Parker Waichman LLP filed nine Plavix bleeding lawsuits in state court in New York.

Read More

Indiana Woman Alleges Serious Injuries From Transvaginal Mesh Products

Indiana Woman Alleges Serious Injuries From Transvaginal Mesh Products

Parker Waichman LLP, a national law firm, just filed a lawsuit on behalf of a woman who suffered injuries after receiving transvaginal mesh implants. The lawsuit suit alleges that the transvaginal mesh created an unreasonable risk and directly caused her injuries.

Read More

$18 Million Settlement Finalized over Flushmate Exploding Toilets

flushmate_explosionAn $18 million settlement is being finalized over Flushmate exploding toilets, manufactured by Sloan Valve Company. The initial lawsuit, originally filed in 2012, alleged that the Series 503 Flushmate III Pressure-Assist Flushing System manufactured by Sloan can unexpectedly explode, causing injury and property damage. Continue reading

Posted in Legal News |

Putting Cell Phone in Your Bra could Lead to Breast Cancer, Dr. Oz Warns

Cell-Phone-in-Your-BraDr. Mehmet Oz is warning against placing your cell phone in your bra, a habit that many women do out of convenience. “When it comes to cell phones, the bra has become the new purse,” Dr. Oz said on an episode of the Dr. Oz show that aired Aug. 26th. Continue reading

Posted in Legal News |

Supreme Court Rejection of Pfizer RICO Case Appeal Could Unleash Cases

PfizerThe US Supreme Court’s rejection of  an appeal from drug maker Pfizer, letting stand a First Circuit ruling that the drug company improperly marketed the epilepsy drug Neurontin to Kaiser Foundation Health Plan, could unleash a flood of cases

Pfizer must pay Kaiser $142 million in damages for violating the Racketeer Influenced and Corrupt Organizations (RICO) Act and an additional $65.4 million for violating the California Unfair Competition Law (UCL). Continue reading

Posted in Health Concerns, Pharmaceuticals |

Drug Maker, Teva, Recalls Parkinson’s Disease Medication as it may be “Super Potent”

tevaTeva Pharmaceutical Industries just issued a recall of one lot of its generic Parkinson’s disease combination medication, carbidopa/levodopa, over it potentially containing too much of an active pharmaceutical ingredient.

Teva Pharmaceutical Industries indicated that the recall, which has been deemed a Class II, involved 3,881 bottles of carbidopa/levodopa 25 mg/100 mg, according to FiercePharmaManufacturing. Teva also indicated that stability testing revealed that the recalled carbidopa/levodopa may be what the drug maker described as “super potent.” The voluntary recall is for the entire United States. Continue reading

Posted in Pharmaceuticals, Product Recalls |

Researchers Study Whether Chemicals in the Environment Increase the Risk of Diabetes

Diabetes ConceptResearchers at the University of Buffalo will be studying how chemicals in the environment affect the risk of diabetes and metabolic conditions.  According to an article posted on the university’s website, the National Institute of Environmental Health Sciences has awarded a two-year $436,751 grant to Margarita L. Dubocovich, PhD and Rajendram V. Rajnarayanan, PhD to study this issue.   Continue reading

Posted in Legal News |

FDA Issues Injunction Against BioAnue Laboratories

FDA-Issues-Injunction-Against-BioAnue-LaboratoriesA federal court order demands that BioAnue Laboratories of Rochelle, Georgia stops illegally marketing its products as treatments for disease, the U.S. Food and Drug Administration (FDA) announced on its website. The court order, which was signed on July 23, 2014 in the United States District Court for the Middle District of Georgia, says that BioAnue’s products were sold as supplements but were illegally marketed as treatments for conditions such as cancer, HIV/AIDS, heart disease, chronic obstructive pulmonary disease and diabetes. The FDA did not approve these products for those uses.

In February 2012, the FDA issued a warning lette Continue reading

Posted in Legal News |

Government Will Withhold Up to One Third of Payment Records in Launch of Physician Payment Database

Launch-of-Physician-Payment-DatabaseFor next month’s launch of the Open Payment database showing payments to physicians from pharmaceutical companies and medical device makers, about one-third of the records will be withheld because of data inconsistencies.

The release of payment information – intended to promote greater transparency about possible conflicts of interest in medicine – is mandated under the Physician Payment Sunshine Act, a provision of the 2010 Affordable Care Act, according to the non-profit investigative journalism group ProPublica. Continue reading

Posted in Legal News |

Court’s Discovery Order in C.R. Bard Litigation Expected to Streamline Litigation Process

Court’s-Discovery-Order-in-C-R-Bard-LitigationThe court overseeing the C.R. Bard transvaginal mesh litigation has put new discovery rules in place that are expected to streamline the discovery process in this litigation. The discovery procedures will specifically impact Collection and Preservation of Evidence in a multidistrict litigation (MDL) that was organized over C.R. Bard’s transvaginal mesh devices in the United States District Court, Southern District of West Virginia.

According to the Court, the new rules will provide that “discovery in this proceeding may involve the collection, division, storage, preservation, and production of biomaterials evidence for which special handling, division, storage, and preservation would be warranted.” The Order followed a stipulation requested by the parties involved in the MDL and involved a petition to the Court to enter an “evidence preservation protocol order,” that would be applicable for existing and future actions in the litigation. Continue reading

Posted in Defective Medical Devices, Transvaginal mesh |

DEA Announces Stricter Classification for Hydrocodone Combination Painkillers

DEA-Announces-Stricter-ClassificationThe Drug Enforcement Administration (DEA) has announced the reclassification of hydrocodone combination products from Schedule III to Schedule II under federal law. Schedule II drugs are substances known to be dangerous, prone to abuse, or could lead to severe psychological or physical dependence.

Combination hydrocodone painkiller products were previously regulated as Schedule III products under the law. Schedule III is the DEA category for substances that have accepted medical use, moderate potential for abuse, and the potential for dependency, according to the DEA definition. As a Schedule II substance, hydrocodone combination products will be subject to more stringent prescribing controls, such as bans on refills, Regulatory Affairs Professionals Society (RAPS) reports. Continue reading

Posted in Defective Products, Health Concerns, Pharmaceuticals |

CDC Whistleblower Exposes Data Manipulation in Vaccine and Autism Study

Data-Manipulation-in-Vaccine-and-Autism-StudyAccording to a study by Focus Autism Foundation, a whistleblower revealed the manipulation of scientific data in a 2004 study on autism and age of vaccination with  the measles, mumps, and rubella (MMR) vaccine.

A research scientist working for the Centers for Disease Control and Prevention (CDC) helped Dr. Brian Hooker of the Focus Autism Foundation uncover data manipulation by the CDC that obscured a higher incidence of autism in African-American boys who received the MMR vaccine earlier than 36 months of age.   Continue reading

Posted in Health Concerns |

© 2005-2014 Parker Waichman LLP ®. All Rights Reserved.